| |

How Inflammation, Stress, and Signaling Shape Mesothelioma’s Growth

How Inflammation, Stress, and Signaling Shape Mesothelioma's Growth

Scientists are looking at how long-term inflammation, cell stress, and messed-up cell signaling help mesothelioma cancer cells grow and spread.

By looking at these processes in mesothelioma patients, the scientists can learn more about new ways to treat this aggressive cancer.

Revolutionizing Mesothelioma Treatment

Malignant mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the body’s internal organs. When it grows in the lining of the lungs, it is called pleural mesothelioma. There are about 2,000 cases of pleural mesothelioma in the United States each year.

Mesothelioma is linked to exposure to a toxic mineral called asbestos. It can take decades for symptoms of mesothelioma to appear after a person is exposed to asbestos.

How Inflammation, Stress, and Signaling Shape Mesothelioma’s Growth

Mesothelioma is a rare cancer, so we are still learning about the best ways to treat it. One way to do this is to learn more about how it grows in the body.

One major factor is inflammation. When asbestos gets inside a person’s body, their body will react by turning on its immune system to fight the invading asbestos fibers. This reaction causes irritation in the tissue around the asbestos, and this can lead to the growth of tumors.

This inflammation can lead to something called oxidative stress. The body’s immune response to asbestos in the body causes the release of harmful molecules that can damage cells and tissues. This reaction also contributes to the growth of tumors, just like inflammation.

All this stress on the body’s tissues causes cells to have a hard time communicating properly with each other. The interrupted signaling makes it almost impossible for the body’s tissues to function as they should, which means it is easier for cancer cells to grow and spread.

Scientists have identified these processes as potential targets for future mesothelioma treatments. If scientists can come up with ways to fix inflammation, stress, or improper cell signaling, then they can stop cancer cells from growing.

Disrupting these processes could lead to better treatment outcomes for patients with mesothelioma.

Source

Fiorilla I, Martinotti S, Todesco AM, et al. Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma. Cells. 2023;12(16):2048. Published 2023 Aug 11. doi:10.3390/cells12162048. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10453755/

Similar Posts

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

  • | |

    Micro-RNAs May Offer New Way to Fight Mesothelioma

    Scientists at one of the world’s top mesothelioma research centers, the Asbestos Diseases Research institute in Sydney, Australia, say that restoring the expression of certain micro RNAs in the cells of mesothelioma patients may offer a new way to fight the disease. A microRNA is a small RNA molecule which is involved in the regulation of gene expression. According to a new report in the Annals of Oncology, the Australian scientists found reduced expression of the micro RNA-15 family (miR-15/16) in the cells of mice with mesothelioma. “When malignant pleural mesothelioma cell lines were compared with the normal mesothelial cell line MeT-5A, the downregulation of miR-15/16 was 2- to 10-fold,” they report. This finding is consistent with previous cancer research…

  • | |

    Treatment Uses Herpes Virus to Shrink Mesothelioma Tumors

    Researchers at a hospital in Sheffield, England are testing a potential new mesothelioma treatment based on the same virus that causes herpes. The small-scale trial is the first in the world to test the modified herpes simplex virus, HSV1716, in human mesothelioma patients. HSV1716 has been genetically engineered to infect and kill cancer cells without harming healthy cells. In laboratory studies on mesothelioma and some other cancers, it has been shown to be effective at shrinking tumors while causing limited toxicity. Just as significantly, HSV1716 increased survival rates among mice with various human cancers. The Phase I/II trial at Sheffield Experimental Cancer Medicine Centre is the next stage in development of HSV1716 as a viable mesothelioma treatment. The goal of…

  • | |

    New Mesothelioma Drug Kills Cancer Stem Cells

    Citing “significant enthusiasm within the mesothelioma community”, the manufacturers of a promising new mesothelioma drug say they have begun a major test of the drug in patients. Massachusetts-based Verastem, Inc. focuses on drugs that fight cancer by attacking the stem cells that give rise to them. Earlier this summer, the FDA granted orphan drug status to their stem cell inhibitor, defactinib, for the treatment of mesothelioma. The designation, which is reserved for drugs that fight the rarest of diseases, helps pave the way for testing and faster approval, depending on the results of clinical trials. “Development of a drug that preferentially kills cancer stem cells is a promising approach, as many standard-of-care treatments have been shown to either have no…

  • | |

    Inflammation Both “Friend and Foe” in Mesothelioma

    An immune system response that causes mesothelioma symptoms such as fever, fatigue, and weight loss may also be helpful to clinicians as a way to find and treat the disease. Scientists with The Asbestos Diseases Research Institute in Sydney, Australia make that case that both systemic inflammation (throughout the body) and at the site of a tumor – has long been associated with mesothelioma and other cancers. Inflammation results when the body attempts to address the imbalances of cancer by producing more of certain immune system cells. Some inflammatory markers, such as CD+8 T-cells and C-reactive protein, have been linked to better prognosis in mesothelioma. Other inflammatory markers, such as certain macrophages and a high neutrophil-to-lymphocyte ratio, can signal the…

  • | |

    Mesothelioma Study Finds New Treatment Target

    Immunotherapy, which involves reprogramming T-cells to find and attack cancer cells, is one of the fastest-growing areas of cancer research. One of the biggest challenges of immunotherapy is how to harness the power of T-cells against cancer without also turning them against healthy cells. A new study conducted in Switzerland and published in the Journal of Translational Medicine addressed the problem by reprogramming T-cells to recognize and attack mesothelioma cells that express a specific protein. Fibroblast Activation Protein (FAP) is expressed on the surface of tumor-associated fibroblast cells which are found in the connective tissue of mesothelioma tumors. FAP is also found in mesothelioma cells and may play a role in the start of cancer, as well as the growth…